B. Riley Issues Pessimistic Outlook for CNTA Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Equities researchers at B. Riley decreased their Q1 2025 earnings estimates for shares of Centessa Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.36). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($2.01) EPS and FY2027 earnings at ($2.33) EPS.

A number of other equities analysts have also recently issued reports on CNTA. Guggenheim restated a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ CNTA opened at $14.59 on Monday. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of 1.54. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09. The business has a fifty day simple moving average of $16.48 and a 200 day simple moving average of $16.44. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04.

Insider Buying and Selling

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now directly owns 118,265 shares of the company’s stock, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CTO Tia L. Bush sold 11,000 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now owns 121,503 shares of the company’s stock, valued at approximately $2,048,540.58. The trade was a 8.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 260,168 shares of company stock worth $4,309,568 in the last quarter. 11.59% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth about $31,000. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares during the last quarter. Barclays PLC lifted its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at $162,000. Finally, OMERS ADMINISTRATION Corp bought a new position in Centessa Pharmaceuticals in the 4th quarter valued at $171,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.